FI860914A0 - Fenylkarbamater. - Google Patents

Fenylkarbamater.

Info

Publication number
FI860914A0
FI860914A0 FI860914A FI860914A FI860914A0 FI 860914 A0 FI860914 A0 FI 860914A0 FI 860914 A FI860914 A FI 860914A FI 860914 A FI860914 A FI 860914A FI 860914 A0 FI860914 A0 FI 860914A0
Authority
FI
Finland
Prior art keywords
sub
fenylkarbamater
pharmaceuticals
useful
phenyl carbamates
Prior art date
Application number
FI860914A
Other languages
English (en)
Other versions
FI87197C (fi
FI860914A (fi
FI87197B (fi
Inventor
Marta Weinstock Rosin
Michael Chorev
Zeev Tashma
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11055728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI860914(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of FI860914A0 publication Critical patent/FI860914A0/fi
Publication of FI860914A publication Critical patent/FI860914A/fi
Application granted granted Critical
Publication of FI87197B publication Critical patent/FI87197B/fi
Publication of FI87197C publication Critical patent/FI87197C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/14—Dithiocarbamic acids; Derivatives thereof
    • C07C333/30—Dithiocarbamic acids; Derivatives thereof having sulfur atoms of dithiocarbamic groups bound to other sulfur atoms
    • C07C333/32—Thiuramsulfides; Thiurampolysulfides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
FI860914A 1985-03-05 1986-03-04 Foerfarande foer framstaellning av terapeutiskt aktiva fenylkarbamater FI87197C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL74497A IL74497A (en) 1985-03-05 1985-03-05 Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
IL7449785 1985-03-05

Publications (4)

Publication Number Publication Date
FI860914A0 true FI860914A0 (fi) 1986-03-04
FI860914A FI860914A (fi) 1986-09-06
FI87197B FI87197B (fi) 1992-08-31
FI87197C FI87197C (fi) 1992-12-10

Family

ID=11055728

Family Applications (1)

Application Number Title Priority Date Filing Date
FI860914A FI87197C (fi) 1985-03-05 1986-03-04 Foerfarande foer framstaellning av terapeutiskt aktiva fenylkarbamater

Country Status (25)

Country Link
US (1) US4948807A (fi)
EP (1) EP0193926B3 (fi)
JP (1) JPS61225158A (fi)
KR (1) KR940010764B1 (fi)
AT (1) ATE58130T1 (fi)
AU (1) AU595504B2 (fi)
CA (1) CA1284501C (fi)
CY (2) CY1748A (fi)
DE (2) DE19875046I1 (fi)
DK (1) DK172851B1 (fi)
ES (1) ES8801193A1 (fi)
FI (1) FI87197C (fi)
GR (1) GR860586B (fi)
HK (1) HK130293A (fi)
HU (1) HU201297B (fi)
IE (1) IE58838B1 (fi)
IL (1) IL74497A (fi)
LU (1) LU90312I2 (fi)
MY (1) MY137602A (fi)
NL (1) NL980031I2 (fi)
NZ (1) NZ215348A (fi)
PH (1) PH23325A (fi)
PL (1) PL146301B1 (fi)
PT (1) PT82127B (fi)
ZA (1) ZA861653B (fi)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH667001A5 (de) * 1985-09-03 1988-09-15 Hugo Degen Untermatratze.
DE3805744C2 (de) * 1987-03-04 1999-09-23 Novartis Ag Phenylcarbamate zur Hemmung der Acetylcholinesterase
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
US5091583A (en) * 1990-05-07 1992-02-25 Air Products And Chemicals, Inc. Tertiary amine catalysts for polurethanes
IT1271679B (it) * 1994-07-18 1997-06-04 Mediolanum Farmaceutici Srl Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
US20100210590A1 (en) * 1995-09-27 2010-08-19 Northwestern University Compositions and treatments for seizure-related disorders
AU4078997A (en) * 1996-08-22 1998-03-06 New York University Cholinesterase inhibitors for treatment of parkinson's disease
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
HU226526B1 (en) * 1996-12-18 2009-03-30 Teva Pharma Phenylethylamine derivatives, use of them for preparation of pharmaceutical compositions and the pharmaceutical compositions comprising them
ATE377585T1 (de) 1996-12-18 2007-11-15 Teva Pharma Aminoindanderivate
US5962535A (en) * 1997-01-17 1999-10-05 Takeda Chemical Industries, Ltd. Composition for alzheimer's disease
AU5495398A (en) * 1997-01-17 1998-08-07 Takeda Chemical Industries Ltd. Idebenone containing combination agent for treating alzheimer's disease
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
EP2311441A1 (en) * 1998-11-23 2011-04-20 Bonnie M. Davis Dosage formulations for acetylcholinesterase inhibitors
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) * 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
DK1251744T4 (en) 2000-01-28 2015-11-16 Dsm Ip Assets Bv INCREASED PRODUCTION OF LIPIDS CONTAINING polyenoic fatty acids, AT HØJTÆTHEDSKULTURER eukaryotic microbes in fermentors.
US20030153598A1 (en) * 2000-07-25 2003-08-14 Raymond Pratt Methods for treating Parkinson's disease with cholinesterase inhibitors
EP2130538A1 (en) * 2000-03-03 2009-12-09 Eisai R&D Management Co., Ltd. Use of a cholinesterase inhibitor for the delaying the onset of Alzheimer's disease
CA2406383A1 (en) * 2000-04-13 2001-10-25 Mayo Foundation For Medical Education And Research A.beta.42 lowering agents
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US7385076B2 (en) 2002-05-31 2008-06-10 Sun Pharmaceutical Industries Limited Process for the preparation of phenylcarbamates
KR100935615B1 (ko) 2002-06-14 2010-01-07 토야마 케미칼 컴퍼니 리미티드 뇌기능을 개선하는 의약조성물 및 뇌기능을 개선하기 위한방법
UA80841C2 (en) * 2002-10-07 2007-11-12 Univ California Fatty acid amide hydrolase inhibitors, pharmaceutical composition (variants) and method to treat appetite disorders, glaucoma, pain, and related neurological disorders (variants)
CZ293014B6 (cs) * 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
DE10301851A1 (de) * 2003-01-17 2004-07-29 Lts Lohmann Therapie-Systeme Ag Verfahren zur medikamentösen Prophylaxe gegen Vergiftungen durch Cholinesterase-Hemmer, sowie hierfür geeignete Wirkstoffe und Arzneimittel
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
AU2004311577A1 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
KR20070085033A (ko) * 2003-10-21 2007-08-27 코루시드 파마슈티컬즈 인코포레이티드 콜린에스테라제를 억제하고 약리 활성제를 방출하는카르바모일 에스테르
EP1689721B1 (en) 2003-11-26 2010-07-14 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
GB0329284D0 (en) * 2003-12-18 2004-01-21 Avecia Ltd Process
GB2409453A (en) * 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
US20050222123A1 (en) 2004-01-27 2005-10-06 North Shore-Long Island Jewish Research Institute Cholinesterase inhibitors for treating inflammation
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
BRPI0514303A (pt) * 2004-08-11 2008-06-10 Myriad Genetics Inc composição farmacêutica e método para tratar distúrbios neurodegenerativos
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2589102C (en) * 2004-11-02 2013-08-13 Northwestern University Pyridazine compounds and methods for using the compounds to treat inflammatory diseases
ES2615487T3 (es) * 2004-11-08 2017-06-07 Emcure Pharmaceuticals Limited un método eficaz para la preparación de (S)-3-[(1-dimetilamino)etil]-fenil-N-etil-N-metil-carbamato
CA2590533C (en) * 2004-11-23 2010-09-07 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
DK1874282T3 (da) 2005-04-06 2010-10-25 Adamas Pharmaceuticals Inc Fremgangsmåder og præparater til behandling af CNS lidelser
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
JP2009518433A (ja) * 2005-12-09 2009-05-07 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム 神経保護用の低用量ラドスチギルの使用
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
US8158627B2 (en) * 2006-04-28 2012-04-17 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
DE602006015241D1 (de) * 2006-08-17 2010-08-12 Alembic Ltd Verbessertes verfahren zur herstellung von rivastigmin
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
CA2667553A1 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Methods and combination therapies for treating alzheimer's disease
EP2125709A2 (en) 2007-02-02 2009-12-02 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
US8013181B2 (en) 2007-04-10 2011-09-06 Dr. Reddy's Laboratories Limited Preparation of rivastigmine and its salts
CN101707952B (zh) * 2007-04-16 2012-08-29 上海特化医药科技有限公司 一种制备利伐斯的明的方法及其中间体
US7884121B2 (en) 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
CN101795683A (zh) * 2007-07-18 2010-08-04 科露西德医药品公司 用于促进警醒症的方法
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
EP2349976B1 (en) 2008-08-25 2012-12-26 Jubilant Life Sciences Limited A process for producing (s)-3-[(1-dimethylamino)ethyl]phenyl-n-ethyl-n-methyl-carbamate via novel intermediates
US8247405B2 (en) 2008-12-10 2012-08-21 Conopco, Inc. Skin lightening compositions with acetylcholinesterase inhibitors
CN101580482B (zh) * 2009-05-27 2014-04-23 沈阳药科大学 一种重酒石酸盐卡巴拉汀的制备方法和应用
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
CN102134206B (zh) * 2010-01-27 2013-11-20 上海京新生物医药有限公司 一种卡巴拉汀的制备方法
BR112012019923A2 (pt) 2010-02-09 2016-08-09 Univ Johns Hopkins métodos e composições para melhorar a função cognitiva
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2011159910A2 (en) 2010-06-17 2011-12-22 Codexis, Inc. Biocatalysts and methods for the synthesis of (s)-3-(1-aminoethyl)-phenol
WO2012131699A1 (en) 2011-03-30 2012-10-04 Neon Laboratories Ltd. Process for preparation of highly pure 3-dimethylaminophenyl dimethylcarbamate
CN102786441B (zh) * 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
WO2013155506A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc. Novel compositions and methods
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
DK2968220T3 (da) 2013-03-15 2021-06-14 Agenebio Inc Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2015022418A1 (en) 2013-08-16 2015-02-19 Takeda Gmbh Treatment of cognitive impairment with pde4 inhibitor
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1905990A (en) * 1931-01-02 1933-04-25 Hoffmann La Roche Disubstituted carbamic acid esters of phenols containing a basic constituent
US2208485A (en) * 1937-04-24 1940-07-16 Hoffmann La Roche Process for the manufacture of disubstituted carbamic acid esters of phenols containing a basic substituent
US2362508A (en) * 1940-12-06 1944-11-14 Merck & Co Inc Therapeutic substances
US2493710A (en) * 1947-03-21 1950-01-03 Hoffmann La Roche Carbamic acid esters
DE1037753B (de) * 1956-07-13 1958-08-28 Rohm & Haas Schaedlingsbekaempfungsmittel

Also Published As

Publication number Publication date
IL74497A (en) 1990-02-09
JPS61225158A (ja) 1986-10-06
IE58838B1 (en) 1993-11-17
ES8801193A1 (es) 1988-01-01
ES552627A0 (es) 1988-01-01
PL146301B1 (en) 1989-01-31
DK172851B1 (da) 1999-08-16
DE19875046I1 (de) 2003-09-04
KR860007207A (ko) 1986-10-08
AU5428486A (en) 1986-09-11
GR860586B (en) 1986-07-07
EP0193926B3 (en) 2010-04-28
LU90312I2 (fr) 1999-01-06
HU201297B (en) 1990-10-28
US4948807A (en) 1990-08-14
HUT41718A (en) 1987-05-28
ZA861653B (en) 1987-10-28
IL74497A0 (en) 1985-06-30
AU595504B2 (en) 1990-04-05
FI87197C (fi) 1992-12-10
CY1748A (en) 1994-06-03
PT82127B (pt) 1988-07-01
FI860914A (fi) 1986-09-06
KR940010764B1 (ko) 1994-11-11
IE860558L (en) 1986-09-05
CA1284501C (en) 1991-05-28
CY2004004I2 (el) 2009-11-04
EP0193926A2 (en) 1986-09-10
DK99186A (da) 1986-09-06
ATE58130T1 (de) 1990-11-15
NL980031I1 (nl) 1999-01-04
FI87197B (fi) 1992-08-31
CY2004004I1 (el) 2009-11-04
EP0193926B1 (en) 1990-11-07
NZ215348A (en) 1990-04-26
DK99186D0 (da) 1986-03-04
DE3675408D1 (de) 1990-12-13
JPH0255416B2 (fi) 1990-11-27
HK130293A (en) 1993-12-03
PT82127A (en) 1986-04-01
NL980031I2 (nl) 1999-03-01
EP0193926A3 (en) 1987-05-13
MY137602A (en) 2009-02-27
PH23325A (en) 1989-07-14

Similar Documents

Publication Publication Date Title
FI860914A0 (fi) Fenylkarbamater.
DE3583779D1 (de) Gelzusammensetzungen von liposomen.
DE3668414D1 (de) Antidiarrhoee-zusammensetzungen.
DE3684564D1 (de) Veterinaere zusammensetzungen.
DE3681140D1 (de) Polyaethylenzusammensetzung.
DE3689555D1 (de) Herstellung von aliphatischen Polyaminen.
DE3684626D1 (de) Schmerzstillende zusammensetzung.
DE3583852D1 (de) Naehrstoffzusammensetzungen.
DE3686740D1 (de) Einkomponenthaertbare zusammensetzung.
DE3689646D1 (de) Antiseptische zusammensetzungen.
DE3586224D1 (de) 3-carbonyl-1-aminoalkyl-1h-indole, verwendbar als analgetika und ihre herstellung.
IT8521212A0 (it) Composizioni covulcanizzabili di fluoroelastomeri.
DE3581238D1 (de) Mikrobiologische herstellung von l-phenylalanin.
DE3650007D1 (de) Herstellung von Maleimid.
IT8519862A0 (it) Composizione di policarbonato autoestinguente.
DE3670063D1 (de) Herstellung von thioantimonaten.
IT8720012A0 (it) Composizione anticorrosione.
DE3578163D1 (de) Herstellung von terpinen-4-olen.
DE3676116D1 (de) Herstellung von azetidin-derivaten.
SU1162191A1 (ru) 1,1-Этилиденди-(5-бром-2-фуроиламин), проявляющий противовоспалительную активность
ATE58368T1 (de) Herstellung von arylestern.
ATE62471T1 (de) Herstellung von hydroxyaraldehyden.
ATE51604T1 (de) Herstellung von thioantimonaten.
SU1297428A1 (ru) 54, 56:58, 60-дииндий (iii) дихлор-6, 11:19, 24:32, 37:45, 50-тетраимино-5-, 52:13, 18:20, 31:39, 44-тетранитрилоктабензо [с, д, е, р, и, у, d, h] (1, 10, 19, 28) - тетраазациклогексатриаконтин как полупроводник
KR880002128U (ko) 휴대용 사무구

Legal Events

Date Code Title Description
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L152

Extension date: 20110303

FG Patent granted

Owner name: PROTERRA AG

MA Patent expired